View this email in your browser
Share Share
Tweet Tweet
Forward Forward


Bringing you our latest news, features and guidance.
November 2021
COVID-19NewsInto practice | Get involved | Blogs Events | Announcements


Updates to our guideline on managing the long-term effects of COVID-19

We have added new recommendations and updated existing recommendations to our rapid guideline on managing the long-term effects of COVID-19. These cover:

We have reviewed the evidence on case definitions, referral to services, children and young people, the impact of vaccines on the long-term effects of COVID-19, signs, symptoms and prevalence and risk factors. We have also updated the list of common symptoms to emphasise that these may be different for children.

Updates to managing COVID-19

We have added new recommendations to our managing COVID-19 guideline on the use of:

We've also updated our recommendations on casirivimab and imdevimab, to clarify that these recommendations apply to people who are hospitalised because of COVID-19.
We are continuously updating our COVID-19 guidelines to incorporate the latest evidence and keep abreast of new developments in diagnosing and treating COVID-19. We’ll highlight recent updates in this monthly email communication, or you can keep up to date on the latest live changes through our website.


ME/CFS woman lying on the bed very tired

ME/CFS guideline outlines steps for improved diagnosis and management

We’ve published an updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS). Our evidence-based recommendations make it clear that any programme based on fixed incremental increases in physical activity or exercise should not be offered. The guideline also recommends cognitive behavioural therapy should only be offered to support people who live with ME/CFS to manage their symptoms, improve their functioning and reduce the distress associated with having a chronic illness.

Generic image of test tubes with DNA strands inside

First long-acting injectable HIV-1 treatment approved

We've published draft guidance recommending cabotegravir with rilpivirine as an option for adults with HIV-1 infection. At present, treatment for HIV involves life-long antiretroviral tablets taken each day. Cabotegravir and rilpivirine are administered as 2 separate injections every 2 months and are a valuable treatment option for people who already have good levels of adherence to daily tablets, but who might prefer an injectable regimen with less frequent dosing.

Draft guideline on safe prescribing and withdrawal management of dependence-forming medicines

Our draft guideline on safe prescribing and withdrawal management advises doctors, nurses and pharmacists to discuss with patients the risks of prescribing certain medicines such as opioids, sleeping pills and antidepressants. People who are taking, or considering coming off dependence forming drugs should have regular review meetings with their doctor, nurse or pharmacist. Consultation on our draft recommendations is open until Thursday 2 December 2021.

Draft guidance recommends dapagliflozin for chronic kidney disease (CKD)

Our draft guidance recommends dapagliflozin as an option for treating some adults with CKD. Dapagliflozin is a promising treatment for chronic kidney disease as it has the potential to increase the length of time before the disease gets worse. The manufacturer estimates up to 91,000 people could be eligible for this treatment in England.

Catch up on all our latest news

Into practice

NEW impact report on learning disabilities

Our latest impact report explores how our guidance for people with a learning disability has been implemented across the health and social care system over recent years. Data collected shows that while some positive change has occurred, health inequality persists. Recommendations to address this challenge include a range of cross-system actions in priority areas that aim to support improving health for people with a learning disability.

NICE impact reports review how our guidance is being used to improve health and care outcomes. The reports are based on data showing the uptake of our guidance and quality statement measures from national audits, reports, surveys and indicator frameworks.

Read learning disabilities impact report

Get involved

Comment on a consultation

Our current consultations include:

Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
See all our open consultations

Join a committee

We have a number of vacancies for health professionals and lay people to join our committees. Topics include asthma monitoring and management, gambling diagnosis and tobacco dependence treatment. Join us and have an active role in producing a guideline or quality standard.

See all our committee vacancies

Observe a meeting

We’re currently holding all our public meetings virtually. You'll need to register in advance to join. 

Upcoming public meeting:

  • Friday 10 December 2021 – Medical technologies advisory committee
    Registration closes Friday 3 December 2021.
    Agenda and register
Our advisory committee meetings, technology appraisal appeal hearings and public board meetings are open to the public. Holding them in public supports our commitment to having processes in place that are rigorous, open, and transparent.
See all our public meetings


Blue landscape with glowing particles

Supporting developers and adopters of AI technologies

Clíodhna Ní Ghuidhir and Rebecca Boffa, principal and senior scientific advisers at NICE, outline the challenges that developers of artificial intelligence technologies face when navigating the path to market and advise on what can be done to avoid them. It’s based on their experience of working to develop a multi-agency advisory service aimed at creating a single source of information and guidance for both developers and adopters of these technologies.

Read the blog post


Improving patient access to the best digital health innovations

NICE is running a free online event:

  • Rapid, robust and responsive: a NICE approach to improving patient access to the best digital health innovations
    Monday 13 December 2021, 11:30am to 12:45pm.
Join to learn more about how NICE is:
  • becoming more flexible and responsive to improve access to the very best digital health technologies, including artificial intelligence and data-driven technologies
  • working more collaboratively and strengthening its capability, to ensure it is at the forefront of anticipating and rapidly evaluating emerging digital health technologies
  • developing best practice guidance and setting universal evidence standards for digital health technologies.
Register for your free ticket


Professor Bee Wee

Professor Bee Wee CBE appointed new non-executive director

The Department of Health and Social Care has announced the appointment of Professor Bee Wee CBE as a new non-executive director at NICE. Professor Bee Wee is national clinical director for end of life care for NHS England and NHS Improvement.


unsubscribe from this list